GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Response Genetics Inc (OTCPK:RGDXQ) » Definitions » ROC %

RGDXQ (Response Genetics) ROC % : -123.51% (As of Mar. 2015)


View and export this data going back to 2007. Start your Free Trial

What is Response Genetics ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Response Genetics's annualized return on capital (ROC %) for the quarter that ended in Mar. 2015 was -123.51%.

As of today (2024-09-22), Response Genetics's WACC % is 0.00%. Response Genetics's ROC % is 0.00% (calculated using TTM income statement data). Response Genetics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Response Genetics ROC % Historical Data

The historical data trend for Response Genetics's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Response Genetics ROC % Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -157.40 -171.60 -139.02 -140.03 -99.08

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -196.85 -197.19 -297.62 -123.51 -

Response Genetics ROC % Calculation

Response Genetics's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2015 is calculated as:

ROC % (A: Dec. 2015 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2014 ) + Invested Capital (A: Dec. 2015 ))/ count )
=-21.377 * ( 1 - 5.54% )/( (17.788 + 22.972)/ 2 )
=-20.1927142/20.38
=-99.08 %

where

Response Genetics's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2015 is calculated as:

ROC % (Q: Mar. 2015 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2014 ) + Invested Capital (Q: Mar. 2015 ))/ count )
=-14.564 * ( 1 - 0% )/( (17.788 + 5.796)/ 2 )
=-14.564/11.792
=-123.51 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2015) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Response Genetics  (OTCPK:RGDXQ) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Response Genetics's WACC % is 0.00%. Response Genetics's ROC % is 0.00% (calculated using TTM income statement data). Response Genetics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Response Genetics ROC % Related Terms

Thank you for viewing the detailed overview of Response Genetics's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Response Genetics Business Description

Traded in Other Exchanges
N/A
Address
201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.
Executives
Roberto Mignone 10 percent owner C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016
Bridger Management Llc 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Swiftcurrent Offshore Ltd 10 percent owner C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104
David Schreiber director 15 TROTTERS LANE, MONROE CT 06468
Sam Chawla director 1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033
Van Den Broek Richard director 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Kevin Roy Harris officer: Vice President and CFO 345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210
Kirk K Calhoun director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Michael Serruya director C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033
Thomas A Bologna director, officer: Chief Executive Officer 4390 US ROUTE ONE, PRINCETON NJ 08540
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Partners Swiftcurrent 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Bridger Capital Llc 10 percent owner 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016
Plc Glaxosmithkline 10 percent owner 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A Metzger director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451

Response Genetics Headlines

From GuruFocus

Response Genetics Inc. (RGDX) CFO Thomas Stankovich buys 7,000 Shares

By GuruFocus Research GuruFocus Editor 12-14-2009